When was ScreenIn3D founded?

ScreenIn3D was founded in 2018 and raised its 1st funding round 7 years after it was founded.

Where is ScreenIn3D located?

ScreenIn3D is headquartered in Cambridge, United States.

How many employees does ScreenIn3D have?

As of Jun 30, 2026, the latest employee count at ScreenIn3D is 10.

Is ScreenIn3D a funded company?

ScreenIn3D is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 12, 2025.

When was the latest funding round of ScreenIn3D?

ScreenIn3D's latest funding was a $***** Seed round on Jun 12, 2025, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $909M in funding in 2026 to date.

Where does ScreenIn3D rank among its competitors?

ScreenIn3D ranks 178th amongst 517 active competitors, of which 149 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of ScreenIn3D?

ScreenIn3D's top competitors include Natera, Guardant Health and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

ScreenIn3D - 2026 Company Profile, Team, Funding & Competitors

Company Details

Revolutionizing drug discovery with predictive 3D human disease models. The company accelerates drug screening using cutting-edge technologies. They offer solutions for testing drug efficacy on predictive 3D human models of disease at scale, enabling faster and better data for small molecules, biologics, cell, and gene therapies. Their versatile platform supports testing multiple modalities, empowering drug developers to produce better drugs, faster, and with less cost. They provide large throughput, relevant models mimicking human disease environments, and customer-defined assays. The open platform is automation-friendly, supporting multiple readouts. They offer lab-on-a-chip solutions, disease models, and services to revolutionize clinical trials. This is a B2B tech company offering software solutions for the pharmaceutical industry.

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Seed

Total Funding

$1.01M in 1 round

Latest Funding Round

Seed, Jun 12, 2025, $*****

Investors

Tricapital & 4 more

Ranked

178^th among 517 active competitors

Employee Count

10 as on Jun 30, 2026

Similar Companies

Natera & 662 more

View ScreenIn3D's full profile

ScreenIn3D has raised a total funding of $1.01M over 1 round. Its latest funding round was a Seed round on Jun 12, 2025 for $*****. 5 investors participated in its latest round. ScreenIn3D has 5 institutional investors.

Here is the list of recent funding rounds of ScreenIn3D:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 12, 2025	5975059	Seed	2238682	6445107	2416027	1831308

Access funding benchmarks and valuations. Sign up today!

View details of ScreenIn3D's funding rounds and investors

ScreenIn3D's employee count trend

ScreenIn3D has 10 employees as of Jun 26. Here is ScreenIn3D's employee count trend over the years:

Uncover ScreenIn3D's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ScreenIn3D include Natera, Guardant Health and Myriad Genetics. Here is the list of Top 10 competitors of ScreenIn3D, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, SoftBank Vision Fund & 25 others	75/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Google Ventures, Deerfield & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
7th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
8th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	66/100
9th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
10th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Orbimed, DFJ Growth & 19 others	63/100
178th	ScreenIn3D 2018, Cambridge (United States), Seed	Revolutionizing drug discovery with predictive 3D human disease models	$1.01M	Gabriel Investments, Scottish Enterprise & 3 others	34/100